Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

BMC cancer - 18 Nov 2010

Pignochino Ymera, Sarotto Ivana, Peraldo-Neia Caterina, Penachioni Junia Y, Cavalloni Giuliana, Migliardi Giorgia, Casorzo Laura, Chiorino Giovanna, Risio Mauro, Bardelli Alberto, Aglietta Massimo, Leone Francesco

Abstract excerpt

BACKGROUND: Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited therapeutic options. Therefore, it is crucial to combine standard therapies with molecular targeting. In this study EGFR, HER2, and their molecular transducers were analysed in terms of mutations, amplifications...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma

Share to Deoxycytidine

Share to Gallbladder Neoplasms

Share to Gemcitabine

Share to Gene Amplification

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 21087480
DOI: 10.1186/1471-2407-10-631
PMCID: PMC3000850

Genes

EGFR
BTC
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21087480-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.PMID 21087480Read ↗

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.Semantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.Semantic proximity Read ↗

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Semantic proximity Read ↗

Systemic treatment of advanced or recurrent biliary tract cancer.Semantic proximity Read ↗

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.Semantic proximity Read ↗

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.Semantic proximity Read ↗

Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision MedicineSemantic proximity Read ↗

Targeted therapies in advanced biliary malignancies: a clinical review.Semantic proximity Read ↗

Systemic treatment options for advanced biliary tract carcinoma.Semantic proximity Read ↗

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.Semantic proximity Read ↗

Molecular genetics and targeted therapeutics in biliary tract carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.